MyChesCo on MSN7h
Johnson & Johnson Reports Positive Study Results for Ulcerative Colitis Treatment
HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...
Healio2d
Positive results showcase icotrokinra’s ‘unique’ mechanism of action in plaque psoriasis
Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
PharmExec2d
Icotrokinra Demonstrates Promise in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
Applied Clinical Trials Online1d
Johnson & Johnson’s Icotrokinra Succeeds Across Multiple Trials in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.
Investor's Business Daily on MSN3d
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
GlobalData on MSN3d
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...
Fierce Biotech4d
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Protagonist reports top line results from Phase 2b study of icotrokinra
Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
BioSpace4d
J&J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...